ACE and Abnormal renal physiology: These findings lead to the conclusion thatcombination therapy of ACE inhibitors, angiotensin receptor antagonists, andbeta blockers is not recommended in HFpEF since it is associated with increasedcardiovascular risk and increased risk of renal dysfunction.